228 related articles for article (PubMed ID: 20437564)
1. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.
Moraal B; van den Elskamp IJ; Knol DL; Uitdehaag BM; Geurts JJ; Vrenken H; Pouwels PJ; van Schijndel RA; Meier DS; Guttmann CR; Barkhof F
Ann Neurol; 2010 May; 67(5):667-75. PubMed ID: 20437564
[TBL] [Abstract][Full Text] [Related]
2. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
[TBL] [Abstract][Full Text] [Related]
3. Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine.
Taschner CA; Kirsch EC; Scheffler K; Wetzel SG; Schulte-Mönting J; Kappos L; Radü EW
Magn Reson Imaging; 2005 Apr; 23(3):469-74. PubMed ID: 15862648
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
Massacesi L; Parigi A; Barilaro A; Repice AM; Pellicanò G; Konze A; Siracusa G; Taiuti R; Amaducci L
Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
[TBL] [Abstract][Full Text] [Related]
5. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
6. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
[TBL] [Abstract][Full Text] [Related]
7. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint.
Healy BC; Ikle D; Macklin EA; Cutter G
Mult Scler; 2010 Jul; 16(7):840-7. PubMed ID: 20530124
[TBL] [Abstract][Full Text] [Related]
8. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
9. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y
Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
Bonzano L; Roccatagliata L; Mancardi GL; Sormani MP
Mult Scler; 2009 Sep; 15(9):1043-7. PubMed ID: 19570818
[TBL] [Abstract][Full Text] [Related]
12. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
Waubant E; Sloan R; Andersson PB; Goodkin D
Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy of liver metastases. Comparison of target volumes and dose-volume histograms employing CT- or MRI-based treatment planning.
Pech M; Mohnike K; Wieners G; Bialek E; Dudeck O; Seidensticker M; Peters N; Wust P; Gademann G; Ricke J
Strahlenther Onkol; 2008 May; 184(5):256-61. PubMed ID: 18427756
[TBL] [Abstract][Full Text] [Related]
14. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
15. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
16. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.
Martinelli V; Rocca MA; Annovazzi P; Pulizzi A; Rodegher M; Martinelli Boneschi F; Scotti R; Falini A; Sormani MP; Comi G; Filippi M
Neurology; 2009 Dec; 73(22):1842-8. PubMed ID: 19949030
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
18. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
[TBL] [Abstract][Full Text] [Related]
19. [Abdominal and pelvic segmented T1-weighted echo-planar imaging and MRI. Comparison with T1-TSE and T2-UTSE sequences].
Maubon A; Berger V; Aubas P; Ferru JM; Rouanet JP
J Radiol; 1999 Mar; 80(3):291-6. PubMed ID: 10327336
[TBL] [Abstract][Full Text] [Related]
20. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
Smith ME; Stone LA; Albert PS; Frank JA; Martin R; Armstrong M; Maloni H; McFarlin DE; McFarland HF
Ann Neurol; 1993 May; 33(5):480-9. PubMed ID: 8498825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
